Flunarizine Hydrochloride Dispersible Tablets

Flunarizine hydrochloride is a selective calcium antagonist that can block excessive calcium ions from entering cells across the membrane, preventing damage caused by intracellular calcium overload. This product has no effect on cardiac contraction and conduction.

The main ingredient of this product is flunarizine hydrochloride. Chemical name: (E)-1-[bis(4-fluorophenyl)methyl]-4-(2-propenyl-3-phenyl)piperazine dihydrochloride Chemical structure: Molecular formula: C26H26F2N2·2HCl Molecular weight: 477.42

This product is white tablets.

Prophylactic treatment of typical (with aura) or atypical (without aura) migraine. Symptomatic treatment of vertigo due to vestibular disorders.

1. Preventive treatment of migraine: Starting dose: 2 tablets per night for patients under 65 years old, 1 tablet per night for patients over 65 years old. If depression, extrapyramidal reactions and other unacceptable adverse reactions occur during treatment, the drug should be discontinued in time. If no significant improvement is seen after 2 months of treatment, the patient should be considered to have no response to this product and the drug should be discontinued. Maintenance treatment: If the efficacy is satisfactory and the patient needs maintenance treatment, the dosage should be reduced to 5 days per week (dose as above). However, even if the efficacy of preventive maintenance treatment is significant and well tolerated, the drug should be discontinued after 6 months of treatment and should only be taken again in case of recurrence. 2. Vertigo: The daily dose should be the same as above, but the drug should be discontinued in time after the symptoms are controlled. The initial course of treatment is usually less than 2 months. If there is no improvement in symptoms after 1 month of treatment for chronic vertigo or 2 months of treatment for sudden vertigo, the patient should be considered to have no response to this product and the drug should be discontinued.

The most common adverse reactions are: drowsiness and fatigue. Some patients may also experience weight gain (or increased appetite). These reactions are often transient. The following serious adverse reactions are occasionally seen during long-term use: 1. Depression. Female patients with a history of depression are particularly prone to this reaction. 2. Extrapyramidal symptoms (such as bradykinesia, rigidity, akathisia, oral and mandibular movement disorders, tremors, etc.) are more likely to occur in the elderly. Less common adverse reactions reported are: 1. Gastrointestinal reactions: heartburn, nausea, stomach pain. 2. Central nervous system: insomnia, anxiety. 3. Others: galactorrhea, dry mouth, muscle pain and rash.

Patients who are allergic to this product or any of its ingredients are contraindicated. Patients with a history of depression, Parkinson's disease or other symptoms of extrapyramidal diseases are contraindicated. Patients with acute cerebral hemorrhage are contraindicated.

Precautions for children: Since this drug can pass through the blood-brain barrier, has clear adverse reactions in the central nervous system, and the central nervous system of children is sensitive to drugs, and the metabolic function is relatively weak, although there is no detailed research data on the use of drugs in children, in principle, children should be cautious or avoid using this drug. Precautions for pregnancy and lactation: Animal experiments have shown that this product has no harm to reproduction, embryonic development, pregnancy process and perinatal period. There is no safety data for the use of this product during human pregnancy. Although there is no data on the secretion of this product in human milk, experiments on lactating dogs have shown that flunarizine hydrochloride can be secreted in breast milk, and its breast milk concentration is higher than that in the blood. Therefore, women who take this product are best not to breastfeed. Precautions for the elderly: Since the nervous system of elderly patients is more sensitive and their metabolic capacity is weaker, the dosage should be reduced as appropriate.

When this product is used in combination with alcohol, hypnotics or sedatives, excessive sedation of the central nervous system may occur. This product is not contraindicated for patients using beta-receptor blockers. When used in combination with phenytoin sodium and carbamazepine, the blood concentration of flunarizine can be reduced.

Seal and store in a cool (not exceeding 20°C) dry place.

5mg (based on C26H26F2N2)

24 months

Qingdao Guoda Pharmaceutical Co., Ltd.

• Founded in:

  2002-04-17

• Address:

  No. 750, Jinggangshan Road, Qingdao Economic and Technological Development Zone

• Tax NO.:

  913702117372658985

• Registered Funds:

  26.25 million yuan

• Website:

  Log in to view

• Email:

  Log in to view